Why do hospitals keep running out of generic drugs?
Hospitals face persistent shortages of common generic drugs due to complex market issues affecting production and distribution.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny
The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.
FDA hasn't inspected nearly 2,000 drug plants since before COVID pandemic
FDA inspections of pharmaceutical firms remain significantly behind pre-pandemic levels, raising contamination risks in critical medications.
Amarin Seeks En Banc Review in Skinny Label Inducement
Hikma's petition challenges the Federal Circuit's skinny label jurisprudence, with implications for patent protections in the pharmaceutical sector.
Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
Generic companies using skinny labeling should not receive preferential treatment for inducement purposes, as consistent inducement laws should be applied uniformly.
Why do hospitals keep running out of generic drugs?
Hospitals face persistent shortages of common generic drugs due to complex market issues affecting production and distribution.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny
The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.
FDA hasn't inspected nearly 2,000 drug plants since before COVID pandemic
FDA inspections of pharmaceutical firms remain significantly behind pre-pandemic levels, raising contamination risks in critical medications.
Amarin Seeks En Banc Review in Skinny Label Inducement
Hikma's petition challenges the Federal Circuit's skinny label jurisprudence, with implications for patent protections in the pharmaceutical sector.
Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
Generic companies using skinny labeling should not receive preferential treatment for inducement purposes, as consistent inducement laws should be applied uniformly.